4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole → N-[6-(1H-pyrazol-4-yl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzamide
Reaktionsgleichung
Br[C:2]1[CH:3]=[CH:4][C:5]2[N:6]([N:8]=[C:9]([NH:11][C:12](=[O:19])[C:13]3[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=3)[N:10]=2)[CH:7]=1.CC1(C)C(C)(C)OB([C:28]2[CH:29]=[N:30][NH:31][CH:32]=2)O1>>[NH:30]1[CH:29]=[C:28]([C:2]2[CH:3]=[CH:4][C:5]3[N:6]([N:8]=[C:9]([NH:11][C:12](=[O:19])[C:13]4[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=4)[N:10]=3)[CH:7]=2)[CH:32]=[N:31]1Komponenten
3
Versuchsvorschrift
The title compound was prepared following procedure described for example 112 but starting from N-(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-benzamide ((B5), 95 mg, 0.3 mmol, 1 eq.) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (Boron-Mol, 85 mg, 0.36 mmol, 1.2 mol eq.) as a white solid (6.2 mg, 7%). HPLC, Rt: 2.26 min (purity: 99%). LC/MS M+(ESI): 305.2.
Quellen und Nachweise
- ORD-Eintrag
- ord-8fb407868b424594bfbeac46c3eedf17